Clinical Trial Update: Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, reactogenicity, and immunogenicity of the AMA1-C1/ISA 720 blood-stage malaria vaccine; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• AMA1-C1/ISA 720 malaria vaccine (AMA1-C1/ISA 720)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Malaria | Phase 1 | Status: COMPLETED